Literature DB >> 12704121

Role of innate immune factors in the adjuvant activity of monophosphoryl lipid A.

Michael Martin1, Suzanne M Michalek, Jannet Katz.   

Abstract

Monophosphoryl lipid A (MPL) is a nontoxic derivative of lipopolysaccharide (LPS) that exhibits adjuvant properties similar to those of the parent LPS molecule. However, the mechanism by which MPL initiates its immunostimulatory properties remains unclear. Due to the involvement of Toll-like receptors in recognizing and transducing intracellular signals in response to LPS, the aim of the present study was to determine the ability of MPL to utilize the Toll-like receptor 2 (TLR2) and TLR4. We provide evidence that MPL differentially utilizes TLR2 and TLR4 for the induction of tumor necrosis factor alpha, interleukin 10 (IL-10), and IL-12 by purified human monocytes as well as by human peripheral blood mononuclear cells. Assessment of NF-kappa B activity demonstrated that MPL utilized TLR2 and especially TLR4 for the activation of NF-kappa B p65 by human monocytes. In addition, stimulation of human monocytes by MPL led to an up-regulation of the costimulatory molecules CD80 and CD86, an effect that could be reduced by pretreatment of cells with a monoclonal antibody to TLR2 or TLR4. Analysis of MPL-induced activation of the extracellular signal-regulated kinase (ERK) and p38 mitogen-activated protein (MAP) kinases revealed that MPL utilized both TLR2 and TLR4 for the phosphorylation of ERK1/2, while TLR4 was the predominant receptor involved in the ability of MPL to phosphorylate p38. Moreover, using selective inhibitors for MAP kinase kinase (PD98059) and p38 (SB203580), we show that ERK1/2 exhibited differential effects on production of TNF-alpha and IL-12 p40 by human monocytes, whereas MPL-induced activation of p38 appeared to be predominantly involved in production of IL-10 and IL-12 p40 by MPL-stimulated monocytes. Taken together, these findings aid in understanding the cellular mechanisms by which MPL induces host cell activation and subsequent adjuvant properties.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12704121      PMCID: PMC153245          DOI: 10.1128/IAI.71.5.2498-2507.2003

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  63 in total

1.  Toll-like receptors control activation of adaptive immune responses.

Authors:  M Schnare; G M Barton; A C Holt; K Takeda; S Akira; R Medzhitov
Journal:  Nat Immunol       Date:  2001-10       Impact factor: 25.606

2.  Gram-positive and gram-negative bacteria do not trigger monocytic cytokine production through similar intracellular pathways.

Authors:  L Rabehi; T Irinopoulou; B Cholley; N Haeffner-Cavaillon; M P Carreno
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

3.  Endocytosed HSP60s use toll-like receptor 2 (TLR2) and TLR4 to activate the toll/interleukin-1 receptor signaling pathway in innate immune cells.

Authors:  R M Vabulas; P Ahmad-Nejad; C da Costa; T Miethke; C J Kirschning; H Häcker; H Wagner
Journal:  J Biol Chem       Date:  2001-06-11       Impact factor: 5.157

4.  Prostaglandin E(2) is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer.

Authors:  P Kaliński; P L Vieira; J H Schuitemaker; E C de Jong; M L Kapsenberg
Journal:  Blood       Date:  2001-06-01       Impact factor: 22.113

5.  TLR6: A novel member of an expanding toll-like receptor family.

Authors:  O Takeuchi; T Kawai; H Sanjo; N G Copeland; D J Gilbert; N A Jenkins; K Takeda; S Akira
Journal:  Gene       Date:  1999-04-29       Impact factor: 3.688

6.  Mycobacteria-induced TNF-alpha and IL-10 formation by human macrophages is differentially regulated at the level of mitogen-activated protein kinase activity.

Authors:  N Reiling; A Blumenthal; H D Flad; M Ernst; S Ehlers
Journal:  J Immunol       Date:  2001-09-15       Impact factor: 5.422

7.  Toll-like receptor 2 and 4 (TLR2 and TLR4) agonists differentially regulate secretory interleukin-1 receptor antagonist gene expression in macrophages.

Authors:  Virginia S Carl; Kathleen Brown-Steinke; Martin J H Nicklin; Michael F Smith
Journal:  J Biol Chem       Date:  2002-03-04       Impact factor: 5.157

8.  Dependence of bacterial protein adhesins on toll-like receptors for proinflammatory cytokine induction.

Authors:  George Hajishengallis; Michael Martin; Hakimuddin T Sojar; Ashu Sharma; Robert E Schifferle; Ernesto DeNardin; Michael W Russell; Robert J Genco
Journal:  Clin Diagn Lab Immunol       Date:  2002-03

9.  The adjuvant properties of a nontoxic monophosphoryl lipid A in hyporesponsive and aging mice.

Authors:  M A Tomai; L E Solem; A G Johnson; E Ribi
Journal:  J Biol Response Mod       Date:  1987-04

10.  Mechanisms of monophosphoryl lipid A augmentation of host responses to recombinant HagB from Porphyromonas gingivalis.

Authors:  Qiu-Bo Yang; Michael Martin; Suzanne M Michalek; Jannet Katz
Journal:  Infect Immun       Date:  2002-07       Impact factor: 3.441

View more
  61 in total

1.  Comparing pooled peptides with intact protein for accessing cross-presentation pathways for protective CD8+ and CD4+ T cells.

Authors:  Hongwei Zhang; Hai Hong; Demin Li; Shiwu Ma; Ying Di; Adam Stoten; Neil Haig; Katalin Di Gleria; Zhanru Yu; Xiao-Ning Xu; Andrew McMichael; Shisong Jiang
Journal:  J Biol Chem       Date:  2009-02-04       Impact factor: 5.157

2.  Effect of tape stripping and adjuvants on immune response after intradermal DNA electroporation.

Authors:  Gaëlle Vandermeulen; Liévin Daugimont; Hervé Richiardi; Marie-Lise Vanderhaeghen; Nathalie Lecouturier; Bernard Ucakar; Véronique Préat
Journal:  Pharm Res       Date:  2009-04-21       Impact factor: 4.200

Review 3.  An overview of the cannabinoid type 2 receptor system and its therapeutic potential.

Authors:  Bihua Bie; Jiang Wu; Joseph F Foss; Mohamed Naguib
Journal:  Curr Opin Anaesthesiol       Date:  2018-08       Impact factor: 2.706

4.  Comparison of adaptive and innate immune responses induced by licensed vaccines for Human Papillomavirus.

Authors:  Douglas M Herrin; Emily E Coates; Pamela J Costner; Troy J Kemp; Martha C Nason; Kapil K Saharia; Yuanji Pan; Uzma N Sarwar; Lasonji Holman; Galina Yamshchikov; Richard A Koup; Yuk Ying S Pang; Robert A Seder; John T Schiller; Barney S Graham; Ligia A Pinto; Julie E Ledgerwood
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

5.  IL-33 enhances the kinetics and quality of the antibody response to a DNA and protein-based HIV-1 Env vaccine.

Authors:  Sanghita Sarkar; Michael S Piepenbrink; Madhubanti Basu; Juilee Thakar; Michael C Keefer; Ann J Hessell; Nancy L Haigwood; James J Kobie
Journal:  Vaccine       Date:  2019-03-27       Impact factor: 3.641

6.  Tobacco-induced alterations to Porphyromonas gingivalis-host interactions.

Authors:  Juhi Bagaitkar; Lisa R Williams; Diane E Renaud; Manjunatha R Bemakanakere; Mike Martin; David A Scott; Donald R Demuth
Journal:  Environ Microbiol       Date:  2009-01-23       Impact factor: 5.491

Review 7.  Antigen-specific tolerance in immunotherapy of Th2-associated allergic diseases.

Authors:  Charles B Smarr; Paul J Bryce; Stephen D Miller
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

Review 8.  Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant.

Authors:  C R Casella; T C Mitchell
Journal:  Cell Mol Life Sci       Date:  2008-10       Impact factor: 9.261

9.  Vaccine potentials of an intrinsically unstructured fragment derived from the blood stage-associated Plasmodium falciparum protein PFF0165c.

Authors:  S Olugbile; C Kulangara; G Bang; S Bertholet; E Suzarte; V Villard; G Frank; R Audran; A Razaname; I Nebie; O Awobusuyi; F Spertini; A V Kajava; I Felger; P Druilhe; G Corradin
Journal:  Infect Immun       Date:  2009-09-28       Impact factor: 3.441

Review 10.  Immune mechanisms of protection: can adjuvants rise to the challenge?

Authors:  Amy S McKee; Megan K L MacLeod; John W Kappler; Philippa Marrack
Journal:  BMC Biol       Date:  2010-04-12       Impact factor: 7.431

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.